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There is growing interest in the potential use of 5-HT1A receptor agonists as neuroprotective agents in stroke and tramautic brain injury.
However, a new study using a recombinant 5-HT1A receptor cell line suggests that these agonists may promote as well as inhibit apoptotic
responses. Because heterologously expressed receptors may couple promiscuously to inappropriate signal transduction pathways, the results
should be interpreted with caution.
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coupled receptors (GPCRs); Heterologous expressionSince initial reports more than a decade ago [1,2], many
studies have demonstrated the neuroprotective properties of 5-
HT1A receptor agonists in various preclinical models of
neurotoxicity and cell death [3–7]. The use of these drugs as
neuroprotective agents has reached the early clinical trial phase
[8,9]. Thus, the demonstration by Turner et al. [10], that in non-
neuronal CHO cells heterologously expressing the 5-HT1A
receptor, receptor agonists elicit not only neuroprotective but
apoptotic effects as well, is both timely and a potential cause for
concern. The anti-apoptotic effect of 5-HT1A agonists such as 8-
OH-DPAT, buspirone, ipsapirone and Bay X 7302 (repinotan) in
neuronal cells has been reported to be mediated by a variety of
mechanisms/signaling pathways, including activation of the
anti-apoptotic phosphatidylinositol 3-kinase (PI-3K) pathway,
inhibition of glutamate release (probably via opening of K+
channels leading to membrane hyperpolarization), extracellular-
regulated kinase (Erk)-stimulated Bcl-2 expression or inhibition
of caspase-3 activity, and increased release of the neurite
extension factor S-100β (Table 1).
Turner et al. examined whether non-neuronal 5-HT1A
receptor-expressing CHO cells, often used to investigate the
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doi:10.1016/j.bbamcr.2007.01.003and previously shown to activate Erk signaling [11–16], could
also activate the c-jun-N-terminal kinase (JNK/SAPK) pathway,
one of the stress-activated mitogen-activated protein kinases
(MAPK) which function primarily as mediators of cellular
inflammation and apoptosis. Surprisingly, 5-HT1A receptor-
mediated effects on this MAPK (and the related p38MAPK)
have been little studied. Turner et al. found that the 5-HT1A
receptor agonist 8-OH-DPAT maximally activated JNK activity
(but not p38MAPK) about 4-fold; the activation was sensitive
to blockade by selective 5-HT1A receptor antagonists and
inhibition by pertussis toxin. Moreover, JNK activation was
associated with increased apoptosis, as evidenced by agonist-
induced chromatin condensation and DNA fragmentation.
Interestingly, indirect evidence (increased apoptotic response
after blockade of the upstream activator of Erk, MEK)
suggested that activation of the Erk pathway was anti-apoptotic.
Consequently, it was suggested that 5-HT1A receptors in CHO
cells are coupled to both anti-apoptotic (Erk) and pro-apoptotic
(JNK) pathways, the relative activation of which under specific
conditions would determine the net effect.
Several recent reports stand in sharp contrast to the results
reported by Turner et al. Hsiung et al. [17] provided evidence
that although 8-OH-DPAT activates Erk signaling in 5-HT1A-
expressing CHO cells, the neuroprotective effect is mediated by
activation of the PI-3K/Akt/NF-kappaB pathway and not by Erk
(a more than 100-fold difference in 5-HT1A receptor expression
Fig. 1. Effects of 8-OH-DPAT (0.5 mg/kg, s.c., 30 min) on phosphorylation of
Erk1 and Erk2 in micropunches of rat brain regions. While Erk phosphorylation
in the CA1 region was reduced, the agonist increased activation of Erk in dorsal
raphe, lateral septum and amygdala.
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to the differential results). Moreover, whether Erk is activated
by native 5-HT1A receptors is an open question, since the
receptor was reported not to couple to Erk signaling in
hippocampal cultures [16,18]; indeed, a reduction in Erk
phosphorylation was reported in CA1 hippocampal slices [19]
and we found a similar reduction in hippocampus in vivo [20].
Erk activation by 5-HT1A receptors appears to be very much
microenvironment (i.e. brain region)-dependent, because we
also found that while there was no effect in frontal cortex and
corpus striatum [20], Erk phosphorylation was increased by 8-
OH-DPAT in lateral septum, amygdala and dorsal raphe nucleus
(Fig. 1). Perhaps most germane, no coupling to the JNK
pathway was observed in hippocampus in vivo [20] (other brain
areas were not tested).
Given the uncertain relevance of Erk activation by 5-HT1A
receptors in CHO cells to the neuroprotective outcome in
neuronal tissues and cells, the reported apoptotic effect via
activation of the JNK pathway might seem even more dubious.
It is important to note that whenever a previously undocumen-
ted signaling mechanism for a heterologously expressed
receptor is reported, it is always appropriate to question the
physiological relevance of the finding. The authors quite
correctly do raise the issue of physiological relevance, and, in
the context of discussing the anti-apoptotic response to 5-HT1A
agonists in neuronal tissues, point out that the effect appears to
be mediated by multiple signal transduction pathways that
depend on the cell type and the attendant cellular injury (see
Table 1). This leads to the conclusion that a 5-HT1A receptor-
stimulated pro-apoptotic response mediated by the JNK path-
way is not an unreasonable finding. It has been thoroughly
documented, however, that cell-specific coupling of 5-HT1A
and other GPCRs occurs to specific signal transduction
pathways [21–23]. Indeed, the authors' laboratory has pub-
lished an extensive and thorough review on the subject,Table 1
Signaling mechanisms for 5-HT1A receptor-mediated neuroprotection
Signaling
mechanism/pathway
Tissues/cells:
in vivo/cell culture
Insult Reference
PI-3K/NF-kappaB Fetal rhombencephalic
neurons
EtOH [7,29]
Inhibition of glutamate
release
Rat cortical cells H2O2 [30]
Rat brain Middle
cerebral
[31]
artery
occlusion
Inhibition of caspase-3
activity
Rat cortical cells H2O2 [30]
Erk and PKCα-mediated
inhibition of caspase-3
activity
HN2–5 cells Anoxia [32,33]
K+ channel opening Mouse brain Ischemia [34]
Activation of Bcl-2 Rat brain Ischemia [35]
S100β Rat brain Ischemia [5]
N-18 neuroblastoma Colchicine [36]
Chick embryo
telencephalon/
Rat hippocampus
Glutamate,
staurosporine
[37]specifically as regards the recombinant 5-HT1A receptor [24].
The idea that GPCRs may “promiscuously” couple to multiple
signal transduction pathways, at least partly as a result of
preferential coupling to different G proteins as available [25,26]
has gained considerable currency and evidence [27,28].
Obviously, other factors, in addition to G protein identity,
such as relative expression of receptors and G proteins, the
presence or absence of components of various signaling
pathways, and many other aspects of the cellular environment
are likely to affect the coupling of receptors to specific signaling
pathways. The current finding suggests that 5-HT1A receptors
have the potential to activate stress-activated JNK/SAPK MAP
kinases and thereby elicit injurious effects on cellular survival.
Hopefully, it will stimulate similar investigations utilizing in
vivo or in vitro models of neurotoxicity and apoptosis. The
results could have a significant impact on whether 5-HT1A
receptor agonists continue to be tested as potential neuropro-
tective agents.
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